Previous close | 9.50 |
Open | 9.61 |
Bid | 9.32 x 200 |
Ask | 9.37 x 200 |
Day's range | 9.21 - 9.78 |
52-week range | 4.26 - 16.90 |
Volume | |
Avg. volume | 1,043,662 |
Market cap | 513.438M |
Beta (5Y monthly) | 0.71 |
PE ratio (TTM) | N/A |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
Astria Therapeutics Inc (NASDAQ:ATXS), a biopharmaceutical company focused on the discovery, development, and commercialization of novel therapies to treat debilitating diseases, has reported an insider sale according to a recent SEC filing.
Key Insights Significantly high institutional ownership implies Astria Therapeutics' stock price is sensitive to their...
Christopher Morabito, Chief Medical Officer of Astria Therapeutics Inc (NASDAQ:ATXS), has sold 10,000 shares of the company on January 29, 2024, according to a recent SEC Filing.